Ulcerative Colitis - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Ulcerative Colitis - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Ulcerative Colitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Ulcerative Colitis: Overview
Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon become inflamed and developes tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes bowel to move its content rapidly and empty frequently. Ulcerative colitis begins gradually and become worse over the period of time. Ulcerative colitis also known as inflammatory bowel disease.
Ulcerative colitis symptoms range from mild to severe and varies among affected people. The predominant symptoms in ulcerative colitis is diarrhea, which can be associated with the discharge of blood in the stool. Diarrhea is the dominant complaint in patients suffering from this disease. The patients suffer from frequent bowel movements, which may be small in volume which results to irritability of the inflamed rectum. Other symptoms of ulcerative colitis include abdominal or rectal pain, fever and weight loss. It also causes joint pain, joint swelling, skin problems and eye inflammation.
Accurate and timely diagnosis of ulcerative colitis is important to initiate appropriate treatment. The treatment of ulcerative colitis is multifaceted and includes the use of medications, alterations in diet and nutrition and some surgical procedures to repair or remove affected portions of gastrointestinal tract. Most patients with ulcerative colitis can be managed at the outpatient clinic and treated successfully. Medications such as Beclomethasone propionate and budesonide MMX, are preferred over systemic steroids owing to their superior safety profile.
Report Highlights
This segment of the Ulcerative Colitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ulcerative Colitis Emerging Drugs
It is currently in phase III stage of development for Ulcerative colitis and is being developed by Arena Pharmaceuticals.
In 2019, RINVOQ (Upadacitinib) received USFDA and European Commission approval for adult patients with moderately to severely active rheumatoid arthritis who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib is currently under Phase 3 clinical studies for the treatment of atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.
Further product details are provided in the repor
Ulcerative Colitis: Therapeutic Assessment
This segment of the report provides insights about the different Ulcerative Colitis drugs segregated based on following parameters that define the scope of the report, such as:
Ulcerative Colitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ulcerative Colitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative Colitis drugs.
Ulcerative Colitis Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Ulcerative Colitis - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Ulcerative Colitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Ulcerative Colitis: Overview
Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon become inflamed and developes tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes bowel to move its content rapidly and empty frequently. Ulcerative colitis begins gradually and become worse over the period of time. Ulcerative colitis also known as inflammatory bowel disease.
Ulcerative colitis symptoms range from mild to severe and varies among affected people. The predominant symptoms in ulcerative colitis is diarrhea, which can be associated with the discharge of blood in the stool. Diarrhea is the dominant complaint in patients suffering from this disease. The patients suffer from frequent bowel movements, which may be small in volume which results to irritability of the inflamed rectum. Other symptoms of ulcerative colitis include abdominal or rectal pain, fever and weight loss. It also causes joint pain, joint swelling, skin problems and eye inflammation.
Accurate and timely diagnosis of ulcerative colitis is important to initiate appropriate treatment. The treatment of ulcerative colitis is multifaceted and includes the use of medications, alterations in diet and nutrition and some surgical procedures to repair or remove affected portions of gastrointestinal tract. Most patients with ulcerative colitis can be managed at the outpatient clinic and treated successfully. Medications such as Beclomethasone propionate and budesonide MMX, are preferred over systemic steroids owing to their superior safety profile.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative Colitis R&D. The therapies under development are focused on novel approaches for Ulcerative Colitis.
This segment of the Ulcerative Colitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ulcerative Colitis Emerging Drugs
- Etrasimod: Arena Pharmaceuticals
It is currently in phase III stage of development for Ulcerative colitis and is being developed by Arena Pharmaceuticals.
- Upadacitinib: Abbvie
In 2019, RINVOQ (Upadacitinib) received USFDA and European Commission approval for adult patients with moderately to severely active rheumatoid arthritis who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib is currently under Phase 3 clinical studies for the treatment of atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.
Further product details are provided in the repor
Ulcerative Colitis: Therapeutic Assessment
This segment of the report provides insights about the different Ulcerative Colitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Ulcerative Colitis
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Ulcerative Colitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ulcerative Colitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative Colitis drugs.
Ulcerative Colitis Report Insights
- Ulcerative Colitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Ulcerative Colitis drugs?
- How many Ulcerative Colitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Ulcerative Colitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ulcerative Colitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ulcerative Colitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- AbbVie
- Celgene
- Eli Lilly and Company
- Lipid Therapeutics
- Hoffmann-La Roche
- Arena Pharmaceuticals
- InDex Pharmaceuticals
- EA Pharma
- FYB202 GmbH & Co KG
- Theravance Biopharma
- Boehringer Ingelheim
- Janssen Research & Development
- Lycera
- Eli Lilly and Company
- LG Chem
- Iltoo Pharma
- Immunic
- Hutchison Medipharma
- Tianjin Hemay Pharmaceutical
- GlaxoSmithKline
- Gilead Sciences
- Gossamer Bio
- Eisai
- UCB
- Suzhou Connect Biopharmaceuticals
- Landos Biopharma
- Seres Therapeutics
- Abivax
- Genentech, Inc.
- ParaTech A/S
- I-Mab Biopharma HongKong Limited
- Sublimity Therapeutics Holdco Limited|Dr. Falk Pharma GmbH
- Reistone Biopharma Company Limited
- Qu Biologics Inc.
- PurGenesis Technologies Inc.
- Protagonist Therapeutics, Inc.
- Pfizer
- Palobiofarma SL
- Novartis Pharmaceuticals
- Bristol-Myers Squibb
- Bridge Biotherapeutics
- Amgen
- Applied Molecular Transport
- AbGenomics International, Inc.
- Protalix BioTherapeutics
- LTT Bio-Pharma Co Ltd
- Dongwha pharma
- Seres Therapeutics
- Innovation Pharmaceuticals
- Holy Stone Healthcare
- SLA Pharma
- OSE Immunotherapeutics
- Bridge Biotherapeutics
- Mitsubishi Tanabe Pharma
- Sterna Biologicals GmbH
- Mesoblast
- Oncostellae
- First Wave Bio
- Upadacitinib
- Ozanimod
- Risankizumab
- Mirikizumab
- LT-02
- Etrolizumab
- Etrasimod
- Cobitolimod
- AJM 300
- FYB 202
- TD-1473
- Spesolimab
- Guselkumab
- LYC-30937
- LY3471851
- LC51-0255
- Aldesleukin
- IMU-838
- HMPL-004
- Hemay007
- GSK2831781
- GS-4875
- GLPG3970
- GED-0301
- GB-004
- E6007
- Cimzia
- CBP-307
- BT-11
- Vancomycin
- ABX464
- UTTR1147A
- Trichuris suis ova
- TJ301
- ST-0529
- SHR0302
- QBECO SSI
- PUR 0110
- PN-943
- PF-06687234
- PF-06651600
- PF-06480605
- PBF-677
- LYS 006
- BMS-986165
- BBT-401-1S
- Apremilast
- Brazikumab
- AMT-101
- AbGn-168H
- ABBV-323
- OPRX-106
- LT 0011
- DW2007
- SER-287
- Brilacidin
- IBD98
- ALFA
- OSE-127
- BBT-401
- Amiselimod
- SB012
- Remestemcel-L
- OST-122
- Niclosamide
Introduction
Executive Summary
Ulcerative Colitis: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ulcerative Colitis– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ulcerative Colitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ulcerative Colitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Etrasimod: Arena Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ABBV-323: AbbVie
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AK 101: Akeso Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
FIN-524: Finch Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Ulcerative Colitis Key Companies
Ulcerative Colitis Key Products
Ulcerative Colitis- Unmet Needs
Ulcerative Colitis- Market Drivers and Barriers
Ulcerative Colitis- Future Perspectives and Conclusion
Ulcerative Colitis Analyst Views
Ulcerative Colitis Key Companies
Appendix
Executive Summary
Ulcerative Colitis: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ulcerative Colitis– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ulcerative Colitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ulcerative Colitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Etrasimod: Arena Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ABBV-323: AbbVie
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AK 101: Akeso Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
FIN-524: Finch Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Ulcerative Colitis Key Companies
Ulcerative Colitis Key Products
Ulcerative Colitis- Unmet Needs
Ulcerative Colitis- Market Drivers and Barriers
Ulcerative Colitis- Future Perspectives and Conclusion
Ulcerative Colitis Analyst Views
Ulcerative Colitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Ulcerative Colitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Ulcerative Colitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Ulcerative Colitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Ulcerative Colitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
